patientMpower

The patientMpower platform is a digital health solution to enable remote monitoring, virtual care and supported self-care of patients with respiratory conditions. The patientMpower digital care solution combines home monitoring of objective and subjective measures with advanced features including inbuilt spirometry data quality control, patient-tailored alerting, automated care work-flows and patient education. The patientMpower platform is a CE marked class I registered medical device. It comprises integrated medical devices, a patient-facing application and a cloud based clinician portal, with onward integration to electronic health records such as EPIC as required. Cellular monitoring options are available to remove digital barriers to care and promote patient inclusion. Monitored parameters include lung function (spirometry), oxygen saturation, body weight, blood pressure, heart rate and rhythm, activity plus validated and bespoke patient reported outcome measures. It is ISO ISO 13485 and ISO 27001 compliant. The platform is intended for use to enable monitoring of adult patients and children aged from 6 years. It has been researched and deployed across a range of respiratory conditions including lung transplantation, interstitial lung disease, COPD, asthma, cystic fibrosis and COVID-19. The platform is also configurable to enable remote monitoring of multiple other (concomitant) conditions, including cardiac conditions (e.g. hypertension, heart failure, arrhythmias). It is typically used by specialist clinical care teams to enable virtual and hybrid models of care, support clinical decision making for patient-centred care and to empower patient self-management. Extensive clinical research has documented the validity, acceptability and utility of the solution. Please refer to https://patientmpower.com/clinical-evidence/ for an up to date evidence repository. Audits and case studies in clinical settings have documented the successful use of the solution to enable the early identification of complications (e.g. rejection, exacerbation, progression) enabling rapid triage and early treatment. The solution has also been shown to decrease the need for out-patient care and clinic based spirometry, with reductions in the range of 40-66% versus standard models of care. patientMpower was first established by CEO Eamonn Costello in 2015. The solution is in use with clinical centres and research organisations across Europe (e.g. ERASMUS MC in the Netherlands), the UK (multiple NHS organisations) and North America (e.g. NYU Langone Health). patientMpower is a commercial organisation. In clinical deployments patientMpower provides access to software as a service under a license agreement. Access for research or as part of a research collaboration depends on the nature of the research and terms of research agreement. patientMpower has focused on delivering continual innovation in digital care, particularly in the research and development of features to improve the clinical efficiency of remote care delivery. The solution is particularly suited to the research and delivery of specialist respiratory care at scale, especially with regard to impact on health outcomes, clinical efficiency measures, health economic outcomes and reimbursement-focused examinations.